Position of the Transparency Council – Brukinsa (zanubrutinib)
At its meeting on 16 January 2023, the Transparency Council adopted opinion No. 7/2023 on the evaluation of the medicine Brukinsa (zanubrutinib) under the drug programme “Treatment of patients with Waldenström macroglobulinaemia (ICD-10: C88.0)”.